Your browser doesn't support javascript.
loading
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee, Jong Woo; Zhang, Yu; Eoh, Kyung Jin; Sharma, Roshan; Sanmamed, Miguel F; Wu, Jenny; Choi, Justin; Park, Hee Sun; Iwasaki, Akiko; Kaftan, Edward; Chen, Lieping; Papadimitrakopoulou, Vali; Herbst, Roy S; Koo, Ja Seok.
Afiliación
  • Lee JW; Section of Medical Oncology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.
  • Zhang Y; Department of Immunobiology, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.
  • Eoh KJ; Section of Medical Oncology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, South Korea.
  • Sharma R; Section of Medical Oncology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.
  • Sanmamed MF; Department of Immunobiology, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.
  • Wu J; Section of Medical Oncology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.
  • Choi J; Section of Medical Oncology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.
  • Park HS; Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea.
  • Iwasaki A; Department of Immunobiology and Molecular, Cellular and Developmental Biology, Yale School of Medicine, New Haven, Connecticut.
  • Kaftan E; Section of Medical Oncology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.
  • Chen L; Department of Immunobiology, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.
  • Papadimitrakopoulou V; Department of Thoracic, Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Herbst RS; Section of Medical Oncology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.
  • Koo JS; Section of Medical Oncology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut; Developmental Therapeutics Translational Research Program, Yale Comprehensive Cancer Center, New Haven, Connecticut. Electronic address: jpeter.koo@yale.ed
J Thorac Oncol ; 14(6): 1046-1060, 2019 06.
Article en En | MEDLINE | ID: mdl-30771521
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteína p53 Supresora de Tumor / Proteínas Proto-Oncogénicas p21(ras) / Inhibidores de Proteínas Quinasas / Antineoplásicos Inmunológicos / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: J Thorac Oncol Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteína p53 Supresora de Tumor / Proteínas Proto-Oncogénicas p21(ras) / Inhibidores de Proteínas Quinasas / Antineoplásicos Inmunológicos / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: J Thorac Oncol Año: 2019 Tipo del documento: Article